STCube Inc Total Liabilities
STCube Inc total liabilities. Based on the latest financial reports, STCube Inc (052020) has total liabilities worth ₩18.51 Billion KRW (≈ $12.54 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STCube Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of STCube Inc (2009–2025)
Total liabilities of STCube Inc from 2009 to 2025. This chart illustrates how STCube Inc's total liabilities have evolved over time, based on quarterly financial data. Explore STCube Inc (052020) investment intensity to see how much of total assets are deployed in long-term investments.
STCube Inc Competitors by Total Liabilities
The table below lists competitors of STCube Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UVAT Technology Co Ltd
TWO:3580
|
Taiwan | NT$917.63 Million |
|
Norsk Titanium AS
OL:NTI
|
Norway | Nkr14.08 Million |
|
Bellevue Group AG
SW:BBN
|
Switzerland | CHF34.51 Million |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
Korea | ₩11.86 Billion |
|
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
|
Indonesia | Rp994.58 Billion |
|
Vardhman Holdings Limited
NSE:VHL
|
India | Rs35.50 Million |
|
Excel Industries Limited
NSE:EXCELINDUS
|
India | Rs4.02 Billion |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$14.34 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down STCube Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of STCube Inc.
Liquidity & Leverage Metrics
STCube Inc Total Liabilities Ratios Explained
STCube Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STCube Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STCube Inc (2009–2025)
The table below shows the annual total liabilities of STCube Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩18.11 Billion ≈ $12.27 Million |
+2.74% |
| 2024-12-31 | ₩17.63 Billion ≈ $11.95 Million |
+65.54% |
| 2023-12-31 | ₩10.65 Billion ≈ $7.22 Million |
+8.11% |
| 2022-12-31 | ₩9.85 Billion ≈ $6.68 Million |
+1.58% |
| 2021-12-31 | ₩9.70 Billion ≈ $6.57 Million |
-32.79% |
| 2020-12-31 | ₩14.43 Billion ≈ $9.78 Million |
-38.77% |
| 2019-12-31 | ₩23.56 Billion ≈ $15.97 Million |
+18.32% |
| 2018-12-31 | ₩19.91 Billion ≈ $13.50 Million |
+171.44% |
| 2017-12-31 | ₩7.34 Billion ≈ $4.97 Million |
-36.40% |
| 2016-12-31 | ₩11.54 Billion ≈ $7.82 Million |
+370.34% |
| 2015-12-31 | ₩2.45 Billion ≈ $1.66 Million |
-74.73% |
| 2014-12-31 | ₩9.70 Billion ≈ $6.58 Million |
-41.65% |
| 2013-12-31 | ₩16.63 Billion ≈ $11.27 Million |
+237.74% |
| 2012-12-31 | ₩4.92 Billion ≈ $3.34 Million |
-9.52% |
| 2011-12-31 | ₩5.44 Billion ≈ $3.69 Million |
+35.83% |
| 2010-12-31 | ₩4.01 Billion ≈ $2.72 Million |
+19.03% |
| 2009-12-31 | ₩3.37 Billion ≈ $2.28 Million |
-- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more